Doctor's Cosmetics OEM Development: A Guide for Dermatologists and Aesthetic Clinics

Doctor's cosmetics is a general term for cosmetics involving physician participation in development. While there is no legal definition, it refers to products where a physician's expertise — such as "supervised by a dermatologist" or "produced by a cosmetic surgeon" — underpins product credibility. The doctor's cosmetics market in Japan is growing, driven by increasing consumer ingredient awareness and demand for evidence-backed products that are "selected or developed by physicians."

Benefits of Physicians Developing OEM Cosmetics

• Unmatched credibility: In the cosmetics market, a physician's recommendation or supervision is the most powerful source of trust. For consumers with sensitive or troubled skin, the fact that "a dermatologist developed this" provides more reassurance than any other marketing message.
• Integration with clinical practice: Physicians who directly observe patient skin conditions in daily practice understand the most common skin concerns and needs. Recommending original products as home care following treatment creates a flow that also helps maintain treatment outcomes.
• Premium pricing potential: Physician-branded products tend to command premium prices. For clinic-exclusive sales, serums priced around ¥10,000 (approx. $70) are commonly accepted.
• Revenue diversification: Cosmetics as a revenue stream independent of medical fees contributes to clinic management stability. This is especially significant for aesthetic clinics focused on self-pay treatments.

Consumer Expectations for Doctor's Cosmetics

What consumers seek from doctor's cosmetics is not "dramatic effects" but "safety and efficacy based on scientific evidence." Low-irritation formulations and a solid approach to including the right ingredients at appropriate concentrations are expected. Uncompromising quality control is essential to avoid betraying the consumer expectation that "it's safe and effective because a doctor made it."

On the other hand, since there is no legal regulation of the term "doctor's cosmetics," low-quality products also exist in the market. By developing products that genuinely leverage a physician's specialized knowledge, you can establish a trusted position in the market.

The first decision when developing doctor's cosmetics is whether to develop the product as a "cosmetic" or a "quasi-drug" (medicated cosmetic under Japanese law). Understanding the advantages and disadvantages of each will help you make the right choice for your business objectives.

Developing as a Cosmetic

• Development timeline: Approximately 6-12 months from formulation development to product launch. No government approval is required, enabling relatively quick market entry.
• Permissible claims: Limited to 56 items such as "conditions the skin" and "provides moisture." Specific skin concern claims (dark spots, wrinkles, acne, etc.) cannot be made.
• Cost: No government approval fees, keeping initial costs lower.
• Flexibility: Formulation changes and improvements are relatively easy, allowing quick reformulation based on market feedback.

Developing as a Quasi-Drug

• Development timeline: Including the approval process, expect 1-2+ years. Timelines can be shortened for active ingredients with existing approval precedents, but novel approvals take even longer.
• Permissible claims: Specific efficacy claims such as "suppresses melanin production to prevent spots and freckles (brightening)," "prevents rough skin," "prevents acne," and "improves wrinkles" can be made.
• Cost: Additional costs for stability testing, safety testing, and approval fees. Even for formulations with existing precedents, expect additional costs of several hundred thousand to several million yen.
• Differentiation: The "medicated" or "quasi-drug" label itself is a powerful consumer appeal. For doctor's cosmetics, the dual credibility of "a medicated cosmetic developed by a physician" creates significant competitive advantage.

Recommended Approach for Physicians

For a first-time brand launch, a phased approach — launching first as a cosmetic, gauging market response, then reformulating the flagship product as a quasi-drug — is practical. Even as a cosmetic, sufficient differentiation is achievable through active ingredient concentrations and formulation quality. Since quasi-drugs require reapplication for any formulation changes after approval, it is more rational to proceed once market needs are confirmed.

However, if the business plan centers differentiation on specific claims such as "brightening" or "acne prevention," developing as a quasi-drug from the outset is also justified. In that case, selecting an OEM manufacturer with extensive quasi-drug approval experience is key to success.

The greatest differentiator for doctor's cosmetics is evidence-based formulation design. By leveraging a physician's specialized knowledge to select ingredients backed by published literature and guidelines, and setting appropriate concentrations, you can create products that stand apart from other cosmetics brands.

Criteria for Active Ingredient Selection

• Availability of clinical evidence: Prioritize ingredients with efficacy reported in peer-reviewed academic papers. Ingredients with human trial (clinical study) data are evaluated as more reliable than those with only in vitro (test tube) data.
• Clarity of mechanism of action: Choose ingredients with a clearly understood biological mechanism of action. Rather than a vague "good for beauty," being able to explain something like "inhibits tyrosinase activity to suppress melanin synthesis" is important.
• Safety profile: Prioritize ingredients with accumulated long-term safety data. When targeting sensitive skin, select ingredients with favorable patch test and stinging test results.
• Stability: Chemical stability within the formulation (resistance to oxidative degradation, hydrolysis, etc.) is also a selection criterion. Unstable ingredients can be addressed through stabilization technologies (encapsulation, derivative forms, pH adjustment, etc.).

Examples of Ingredients and Concentrations (General Knowledge)

• Niacinamide (Vitamin B3): Extensive evidence for brightening, barrier function improvement, and wrinkle reduction. In cosmetics, concentrations of 2-5% are typical, while quasi-drugs require approved concentrations.
• Retinol (Vitamin A): Well-known for wrinkle improvement and turnover promotion. High concentrations can be irritating, so gradual concentration increases and encapsulation are common approaches.
• Ascorbic acid derivatives (Vitamin C derivatives): Antioxidant and brightening effects. Stable derivatives such as ascorbyl glucoside and APPS (palmitoyl ascorbyl phosphate 3Na) are widely used.
• Ceramides: Barrier function repair. Human-type ceramides (ceramide NG, ceramide NP, ceramide AP, etc.) closely match the skin's ceramide composition and have high affinity.

Collaboration with OEM Manufacturers

While physicians are experts in skin physiology and ingredient pharmacology, cosmetic formulation technology (emulsification, thickening, preservation, stabilization) is a separate specialty. Through collaboration with the OEM manufacturer's formulators, you can achieve the goal of "delivering effective ingredients in a stable formulation with a pleasant sensory experience." The ideal division of labor is: the physician determines "what to include and why," while the OEM manufacturer handles "how to formulate it."

Doctor's cosmetics distribution channels broadly fall into "clinic-exclusive" and "general distribution (e-commerce/retail)." Understanding the merits and drawbacks of each will help you build a channel strategy aligned with your brand objectives.

Clinic-Exclusive Model

• Advantages: Post-consultation personalized recommendations lead to high purchase rates. Products are less exposed to price competition, making premium pricing easier to maintain. The exclusivity of "available only at this clinic" elevates brand value.
• Disadvantages: Sales volume is limited by patient traffic. Products are difficult for distant patients to access, creating scalability constraints.
• Practical tips: Place testers in the reception area and consultation rooms, and train staff to explain product features. Having the physician directly recommend "this product" during consultation is enormously effective.

General Distribution Model (E-Commerce/Retail)

• Advantages: No geographic constraints, enabling larger sales volumes. An own-EC-centered approach can also maintain high margins.
• Disadvantages: Entering the open market increases competition and requires advertising investment. The sense of clinic exclusivity may also diminish.
• Hybrid strategy: Separating clinic-exclusive and general-distribution products is effective. Keep high-concentration, premium-priced items as clinic exclusives, while placing more accessibly priced lines into general distribution, preserving brand prestige while scaling volume.

Relationship with Medical Advertising Guidelines

When advertising doctor's cosmetics, medical advertising guidelines must be considered in addition to the PMD Act. Key points to review:

• Use of physician credentials: Stating "developed by the director of XX Dermatology Clinic" is permissible, but expressions implying that the product is as effective as medical treatment are inappropriate.
• Avoiding confusion with clinic advertising: When introducing cosmetics on a clinic website, medical advertising guidelines may apply. Clinic medical information and cosmetics sales pages should be clearly separated.
• Patient testimonials: Under medical advertising rules, using patient testimonials in advertising is generally prohibited. Even in cosmetics advertising, caution is needed when linking testimonials to clinical treatments.
• "Treatment," "cure," and similar expressions: Using medical terminology such as "treatment," "cure," or "improve" in cosmetics advertising violates the PMD Act. Even products involving physicians must stay within the 56 permitted cosmetic efficacy claims.

If you have concerns about advertising expressions, it is strongly recommended to have them reviewed in advance by a specialist (regulatory affairs consultant) with expertise in both the PMD Act and medical advertising regulations.